Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexven is a branded generic antidepressant medication developed and marketed by Lyf Healthcare. Its active ingredient is desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). The drug functions by blocking the reuptake of serotonin and norepinephrine through its interaction with the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby increasing the synaptic concentrations of these neurotransmitters in the brain. Formulated as an oral tablet, Dexven is approved for the treatment of major depressive disorder (depression) and is available in strengths such as 50mg. Common side effects associated with its use include nausea, dizziness, insomnia, constipation, and potential increases in blood pressure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dexven.